This review was conducted to present the main neuroblastoma (NB) clinical characteristics and the most common genetic alterations present in these pediatric tumors, highlighting their impact in tumor cell aggressiveness behavior, including metastatic development and treatment resistance, and patients’ prognosis. The distinct three NB cell lineage phenotypes, S-type, N-type, and I-type, which are characterized by unique cell surface markers and gene expression patterns, are also reviewed. Finally, an overview of the most used NB cell lines currently available for in vitro studies and their unique cellular and molecular characteristics, which should be taken into account for the selection of the most appropriate model for NB pre-clinical studies, is presented. These valuable models can be complemented by the generation of NB reprogrammed tumor cells or organoids, derived directly from patients’ tumor specimens, in the direction toward personalized medicine.
BrodeurGM.Spontaneous regression of neuroblastoma. Cell Tissue Res2018;
372:277–86
4.
JohnsenJIDybergCWickströmM.Neuroblastoma-A neural crest derived embryonal malignancy. Front Mol Neurosci2019;
12:9
5.
MorgensternDALondonWBStephensDVolchenboumSLSimonTNakagawaraAShimadaHSchleiermacherGMatthayKKCohnSLPearsonADIrwinMS.Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: a study from the international neuroblastoma risk group database. Eur J Cancer2016;
65:1–10
6.
ShimadaHUmeharaSMonobeYHachitandaYNakagawaAGotoSGerbingRBStramDOLukensJNMatthayKK.International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the children's cancer group. Cancer2001;
92:2451–61
7.
ShimadaHAmbrosIMDehnerLPHataJJoshiVVRoaldBStramDOGerbingRBLukensJNMatthayKKCastleberryRP.The international neuroblastoma pathology classification (the Shimada system). Cancer1999;
86:364–72
8.
TolbertVPMatthayKK.Neuroblastoma: clinical and biological approach to risk stratification and treatment. Cell Tissue Res2018;
372:195–209
9.
BrodeurGMMinturnJEHoRSimpsonAMIyerRVarelaCRLightJEKollaVEvansAE.Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res2009;
15:3244–50
10.
IyerRVarelaCRMinturnJEHoRSimpsonAMLightJEEvansAEZhaoHThressKBrownJLBrodeurGM.AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts. Cancer Chemother Pharmacol2012;
70:477–86
11.
MeldolesiJ.Neurotrophin Trk receptors: new targets for cancer therapy.Rev Physiol Biochem Pharmacol2018;
174:67–79
12.
LiZZhangYTongYTongJThieleCJ.Trk inhibitor attenuates the BDNF/TrkB-induced protection of neuroblastoma cells from etoposide in vitro and in vivo. Cancer Biol Ther2015;
16:477–83
13.
AygunN.Biological and genetic features of neuroblastoma and their clinical importance. Curr Pediatr Rev2018;
14:73–90
14.
CaoYJinYYuJWangJYanJZhaoQ.Research progress of neuroblastoma related gene variations. Oncotarget2017;
8:18444–55
15.
KamiharaJBourdeautFFoulkesWDMolenaarJJMosséYPNakagawaraAPararedaAScollonSRSchneiderKWSkaletAHStatesLJWalshMFDillerLRBrodeurGM.Retinoblastoma and neuroblastoma predisposition and surveillance. Clin Cancer Res2017;
23:e98–e106
16.
TriggRMTurnerSD.ALK in neuroblastoma: biological and therapeutic implications. Cancers2018;
10:113
17.
DeyellRJAttiyehEF.Advances in the understanding of constitutional and somatic genomic alterations in neuroblastoma. Cancer Genet2011;
204:113–21
18.
MasecchiaSCocoSBarlaAVerriAToniniGP.Genome instability model of metastatic neuroblastoma tumorigenesis by a dictionary learning algorithm. BMC Med Genomics2015;
8:57
19.
Thorner AloopPSThe molecular genetic profile of neuroblastoma. Diagn Histopathol2014;
20:76–83
20.
UryuKNishimuraRKataokaKSatoYNakazawaASuzukiHYoshidaKSekiMHiwatariMIsobeTShiraishiYChibaKTanakaHMiyanoSKohKHanadaROkaAHayashiYOhiraMKamijoTNagaseHTakimotoTTajiriTNakagawaraAOgawaSTakitaJ.Identification of the genetic and clinical characteristics of neuroblastomas using genome-wide analysis. Oncotarget2017;
8:107513–29
21.
HoNPengHMayohCLiuPYAtmadibrataBMarshallGMLiJLiuT.Delineation of the frequency and boundary of chromosomal copy number variations in paediatric neuroblastoma. Cell Cycle2018;
17:749–58
22.
BerbegallAPVillamónEPiquerasMTadeoIDjosAAmbrosPFMartinssonTAmbrosIMCañeteACastelVNavarroSNogueraR.Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors. Oncogene2016;
35:1423–32
23.
BrodeurGMSeegerRCSchwabMVarmusHEBishopJM.Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science1984;
224:1121–4
24.
AttiyehEFLondonWBMosséYPWangQWinterCKhaziDMcGradyPWSeegerRCLookATShimadaHBrodeurGMCohnSLMatthayKKMarisJM; Group CsO.Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med2005;
353:2243–53
25.
StafmanLLBeierleEA.Cell proliferation in neuroblastoma. Cancers2016;
8:13
26.
SlackAChenZTonelliRPuleMHuntLPessionAShohetJM.The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci USA2005;
102:731–6
27.
Van MaerkenTRihaniADreidaxDDe ClercqSYigitNMarineJCWestermannFDe PaepeAVandesompeleJSpelemanF.Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3. Mol Cancer Ther2011;
10:983–93
28.
LiuZThieleCJ.ALK and MYCN: when two oncogenes are better than one. Cancer Cell2012;
21:325–6
29.
YangLLiYWeiZChangX.Coexpression network analysis identifies transcriptional modules associated with genomic alterations in neuroblastoma. Biochim Biophys Acta Mol Basis Dis2018;
1864:2341–8
30.
HenrichKOSchwabMWestermannF.1p36 tumor suppression – a matter of dosage?Cancer Res2012;
72:6079–88
31.
BagchiAPapazogluCWuYCapursoDBrodtMFrancisDBredelMVogelHMillsAA.CHD5 is a tumor suppressor at human 1p36. Cell2007;
128:459–75
32.
CarénHFranssonSEjeskärKKognerPMartinssonT.Genetic and epigenetic changes in the common 1p36 deletion in neuroblastoma tumours. Br J Cancer2007;
97:1416–24
33.
OkawaERGotohTManneJIgarashiJFujitaTSilvermanKAXhaoHMosseYPWhitePSBrodeurGM.Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas. Oncogene2008;
27:803–10
34.
FujitaTIgarashiJOkawaERGotohTManneJKollaVKimJZhaoHPawelBRLondonWBMarisJMWhitePSBrodeurGM.CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J Natl Cancer Inst2008;
100:940–9
35.
KoyamaHZhuangTLightJEKollaVHigashiMMcGradyPWLondonWBBrodeurGM.Mechanisms of CHD5 inactivation in neuroblastomas. Clin Cancer Res2012;
18:1588–97
36.
ThompsonPMGotohTKokMWhitePSBrodeurGM.CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene2003;
22:1002–11
37.
KollaVZhuangTHigashiMNaraparajuKBrodeurGM.Role of CHD5 in human cancers: 10 years later. Cancer Res2014;
74:652–8
38.
HigashiMKollaVIyerRNaraparajuKZhuangTKollaSBrodeurGM.Retinoic acid-induced CHD5 upregulation and neuronal differentiation of neuroblastoma. Mol Cancer2015;
14:150
39.
CraigBTRellingerEJAlvarezALDusekHLQiaoJChungDH.Induced differentiation inhibits sphere formation in neuroblastoma. Biochem Biophys Res Commun2016;
477:255–9
40.
MatthayKKVillablancaJGSeegerRCStramDOHarrisRERamsayNKSwiftPShimadaHBlackCTBrodeurGMGerbingRBReynoldsCP.Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s cancer group. N Engl J Med1999;
341:1165–73
41.
AmbrosPFAmbrosIMBrodeurGMHaberMKhanJNakagawaraASchleiermacherGSpelemanFSpitzRLondonWBCohnSLPearsonADMarisJM.International consensus for neuroblastoma molecular diagnostics: report from the international neuroblastoma risk group (INRG) biology committee. Br J Cancer2009;
100:1471–82
42.
CarénHKryhHNethanderMSjöbergRMTrägerCNilssonSAbrahamssonJKognerPMartinssonT.High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci USA2010;
107:4323–8
43.
TakagiMYoshidaMNemotoYTamaichiHTsuchidaRSekiMUryuKNishiiRMiyamotoSSaitoMHanadaRKanekoHMiyanoSKataokaKYoshidaKOhiraMHayashiYNakagawaraAOgawaSMizutaniSTakitaJ.Loss of DNA damage response in neuroblastoma and utility of a PARP inhibitor. J Natl Cancer Inst2017;
109:djx062
44.
MlakarVJurkovic MlakarSLopezGMarisJMAnsariMGumy-PauseF.11q deletion in neuroblastoma: a review of biological and clinical implications. Mol Cancer2017;
16:114
45.
RibellesAJBarberaSYanezYGargalloPSeguraVJuanBNogueraRPiquerasMFornes-FerrerVde MoraJFCaneteACastelV.Clinical features of neuroblastoma with 11q deletion: an increase in relapse probabilities in localized and 4S stages. Sci Rep2019;
9:13806
46.
MichelsEHoebeeckJDe PreterKSchrammABrichardBDe PaepeAEggertALaureysGVandesompeleJSpelemanF.CADM1 is a strong neuroblastoma candidate gene that maps within a 3.72 Mb critical region of loss on 11q23. BMC Cancer2008;
8:173
47.
HoebeeckJMichelsEPattynFCombaretVVermeulenJYigitNHoyouxCLaureysGDe PaepeASpelemanFVandesompeleJ.Aberrant methylation of candidate tumor suppressor genes in neuroblastoma. Cancer Lett2009;
273:336–46
48.
MurakamiY.Involvement of a cell adhesion molecule, TSLC1/IGSF4, in human oncogenesis. Cancer Sci2005;
96:543–52
49.
HartsoughEJWeissMBHeilmanSAPurwinTJKugelCH3rdRosenbaumSRErkesDATiagoMHooKimKChervonevaIAplinAE.CADM1 is a TWIST1-regulated suppressor of invasion and survival. Cell Death Dis2019;
10:281
50.
Gumy-PauseFPardoBKhoshbeen-BoudalMAnsariMGayet-AgeronASappinoAPAttiyehEFOzsahinH.GSTP1 hypermethylation is associated with reduced protein expression, aggressive disease and prognosis in neuroblastoma. Genes Chromosomes Cancer2012;
51:174–85
51.
NowackiSSkowronMOberthuerAFaginAVothHBrorsBWestermannFEggertAHeroBBertholdFFischerM.Expression of the tumour suppressor gene CADM1 is associated with favourable outcome and inhibits cell survival in neuroblastoma. Oncogene2008;
27:3329–38
52.
CombaretVBrejonSIaconoISchleiermacherGPierronGRibeiroABergeronCMarabelleAPuisieuxA.Determination of 17q gain in patients with neuroblastoma by analysis of circulating DNA. Pediatr Blood Cancer2011;
56:757–61
53.
KuzykAGartnerJMaiS.Identification of neuroblastoma subgroups based on three-dimensional telomere organization. Transl Oncol2016;
9:348–56
54.
GodfriedMBVeenstraMV SluisPBoonKV AsperenRHermusMCV SchaikBDVoûteTPSchwabMVersteegRCaronHN.The N-myc and c-myc downstream pathways include the chromosome 17q genes nm23-H1 and nm23-H2. Oncogene2002;
21:2097–101
55.
KronaCCarénHSjöbergRMSandstedtBLaureysGKognerPMartinssonT.Analysis of neuroblastoma tumour progression; loss of PHOX2B on 4p13 and 17q gain are early events in neuroblastoma tumourigenesis. Int J Oncol2008;
32:575–83
56.
MurrayMRStoutAP.Distinctive characteristics of the sympathicoblastoma cultivated in vitro: a method for prompt diagnosis. Am J Pathol1947;
23:429–41
57.
ChakrabartiLAbou-AntounTVukmanovicSSandlerAD.Reversible adaptive plasticity: a mechanism for neuroblastoma cell heterogeneity and chemo-resistance. Front Oncol2012;
2:82
58.
Dagogo-JackIShawAT.Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol2018;
15:81–94
59.
CiccaroneVSpenglerBAMeyersMBBiedlerJLRossRA.Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages. Cancer Res1989;
49:219–25
60.
RossRASpenglerBABiedlerJL.Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J Natl Cancer Inst1983;
71:741–7
61.
van GroningenTAkogulNWesterhoutEMChanAHasseltNEZwijnenburgDABroekmansMStroekenPHaneveldFHooijerGKJSavci-HeijinkCDLakemanAVolckmannRvan SluisPValentijnLJKosterJVersteegRvan NesJ.A NOTCH feed-forward loop drives reprogramming from adrenergic to mesenchymal state in neuroblastoma. Nat Commun2019;
10:1530
62.
CohenNBettsDRRechaviGAmariglioNTrakhtenbrotL.Clonal expansion and not cell interconversion is the basis for the neuroblast and nonneuronal types of the SK-N-SH neuroblastoma cell line. Cancer Genet Cytogenet2003;
143:80–4
63.
GoranovBBRedfernCP.Cytogenetic differences and neuroblastoma cell interconversion. Cancer Genet Cytogenet2004;
149:173–4
64.
CimminoFPezoneLAvitabileMAciernoGAndolfoICapassoMIolasconA.Inhibition of hypoxia inducible factors combined with all-trans retinoic acid treatment enhances glial transdifferentiation of neuroblastoma cells. Sci Rep2015;
5:11158
65.
WaltonJDKattanDRThomasSKSpenglerBAGuoHFBiedlerJLCheungNKRossRA.Characteristics of stem cells from human neuroblastoma cell lines and in tumors. Neoplasia2004;
6:838–45
66.
RossRAWaltonJDHanDGuoHFCheungNK.A distinct gene expression signature characterizes human neuroblastoma cancer stem cells. Stem Cell Res2015;
15:419–26
67.
BellNHannVRedfernCPCheekTR.Store-operated Ca(2+) entry in proliferating and retinoic acid-differentiated N- and S-type neuroblastoma cells. Biochim Biophys Acta2013;
1833:643–51
68.
CoreyJMGertzCCSuttonTJChenQMycekKBWangBSMartinAAJohnsonSLFeldmanEL.Patterning N-type and S-type neuroblastoma cells with pluronic F108 and ECM proteins. J Biomed Mater Res A2010;
93:673–86
69.
RossRABiedlerJLSpenglerBA.A role for distinct cell types in determining malignancy in human neuroblastoma cell lines and tumors. Cancer Lett2003;
197:35–9
70.
WhitworthCLRedfernCPFCheekTR.Differentiation-induced remodelling of store-operated calcium entry is independent of neuronal or glial phenotype but modulated by cellular context. Mol Neurobiol2019;
56:857–72
71.
GoodsonHVJonassonEM.Microtubules and microtubule-associated proteins. Cold Spring Harb Perspect Biol2018;
10:a022608
72.
HagenbuchnerJLungkoflerLKiechl-KohlendorferUViolaGFerlinMGAusserlechnerMJObexerP.The tubulin inhibitor MG-2477 induces autophagy-regulated cell death, ROS accumulation and activation of FOXO3 in neuroblastoma. Oncotarget2017;
8:32009–26
73.
ParkerALKavallarisMMcCarrollJA.Microtubules and their role in cellular stress in cancer. Front Oncol2014;
4:153
74.
DonSVerrillsNMLiawTYLiuMLNorrisMDHaberMKavallarisM.Neuronal-associated microtubule proteins class III beta-tubulin and MAP2c in neuroblastoma: role in resistance to microtubule-targeted drugs. Mol Cancer Ther2004;
3:1137–46
75.
LiuJLiY.Upregulation of MAPK10, TUBB2B and RASL11B may contribute to the development of neuroblastoma. Mol Med Rep2019;
20:3475–86
76.
BoumilEFVohnoutkaRLeeSPantHSheaTB.Assembly and turnover of neurofilaments in growing axonal neurites. Biol Open2018;
7:bio028795
77.
HoCLLiemRK.Intermediate filaments in the nervous system: implications in cancer. Cancer Metastasis Rev1996;
15:483–97
78.
PalHASinghASheikhPAPanjlaAKumarAVermaS.Peptide-based scaffold for nitric oxide induced differentiation of neuroblastoma cells. Chembiochem2018;
19:1127–31
79.
CalmonMFJeschkeJZhangWDhirMSiebenkäsCHerreraATsaiHCO'HaganHMPappouEPHookerCMFuTSchuebelKEGabrielsonERahalPHermanJGBaylinSBAhujaN.Epigenetic silencing of neurofilament genes promotes an aggressive phenotype in breast cancer. Epigenetics2015;
10:622–32
80.
EncinasMIglesiasMLiuYWangHMuhaisenACeñaVGallegoCComellaJX.Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. J Neurochem2000;
75:991–1003
81.
TeppolaHSarkanenJRJalonenTOLinneML.Morphological differentiation towards neuronal phenotype of SH-SY5Y neuroblastoma cells by estradiol, retinoic acid and cholesterol. Neurochem Res2016;
41:731–47
82.
FoleyJWitteDChiuFCParysekLM.Expression of the neural intermediate filament proteins peripherin and neurofilament-66/alpha-internexin in neuroblastoma. Lab Invest1994;
71:193–9
83.
KovalevichJLangfordD.Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology. Methods in Molecular Biology (Clifton, NJ)2013;
1078:9–21
84.
XieHRHuLSLiGY.SH-SY5Y human neuroblastoma cell line: in vitro cell model of dopaminergic neurons in Parkinson’s disease. Chin Med J2010;
123:1086–92
85.
CubellsJFZabetianCP.Human genetics of plasma dopamine beta-hydroxylase activity: applications to research in psychiatry and neurology. Psychopharmacology (Berl)2004;
174:463–76
86.
SamaraweeraLGrandinettiKBHuangRSpenglerBARossRA.MicroRNAs define distinct human neuroblastoma cell phenotypes and regulate their differentiation and tumorigenicity. BMC Cancer2014;
14:309
BasakranNS.CD44 as a potential diagnostic tumor marker. Saudi Med J2015;
36:273–9
89.
SenbanjoLTChellaiahMA.CD44: a multifunctional cell surface adhesion receptor is a regulator of progression and metastasis of cancer cells. Front Cell Dev Biol2017;
5:18
90.
ChenCZhaoSKarnadAFreemanJW.The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol2018;
11:64
91.
WangZZhaoKHackertTZöllerM.CD44/CD44v6 a reliable companion in cancer-initiating cell maintenance and tumor progression. Front Cell Dev Biol2018;
6:97
ZollingerAJSmithML.Fibronectin, the extracellular glue. Matrix Biol2017;
60-61:27–37
94.
JiaDEnterszIButlerCFotyRA.Fibronectin matrix-mediated cohesion suppresses invasion of prostate cancer cells. BMC Cancer2012;
12:94
95.
RickJWChandraADalle OreCNguyenATYagnikGAghiMK.Fibronectin in malignancy: Cancer-specific alterations, protumoral effects, and therapeutic implications. Semin Oncol2019;
46:284–90
96.
BattagliaRADelicSHerrmannHSniderNT.Vimentin on the move: new developments in cell migration. F1000Res2018;
7:1796
97.
De PascalisCPerez-GonzalezCSeetharamanSBoedaBVianayBBuruteMLeducCBorghiNTrepatXEtienne-MannevilleS.Intermediate filaments control collective migration by restricting traction forces and sustaining cell-cell contacts. J Cell Biol2018;
217:3031–44
98.
DubeyMHodaSChanWKPimentaAOrtizDDSheaTB.Reexpression of vimentin in differentiated neuroblastoma cells enhances elongation of axonal neurites. J Neurosci Res2004;
78:245–9
99.
BackhovensHGheuensJSlegersH.Expression of glial fibrillary acidic protein in rat C6 glioma relates to vimentin and is independent of cell-cell contact. J Neurochem1987;
49:348–54
100.
SatelliALiS.Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci2011;
68:3033–46
101.
QiSZhengJZhuHYangLXiaoX.Identification of neuroblastoma stem cells by characterization of side population cells in the human neuroblastoma SK-N-SH cell line. J Pediatr Surg2010;
45:2305–11
102.
RossRASpenglerBA.Human neuroblastoma stem cells. Semin Cancer Biol2007;
17:241–7
103.
LiWLeeMRKimTKimYWChoMY.Activated STAT3 may participate in tumor progression through increasing CD133/survivin expression in early stage of Colon cancer. Biochem Biophys Res Commun2018;
497:354–61
104.
MizrakDBrittanMAlisonM.CD133: molecule of the moment. J Pathol2008;
214:3–9
105.
KimKWKimJYQiaoJClarkRAPowersCMCorreaHChungDH.Dual-targeting AKT2 and ERK in cancer stem-like cells in neuroblastoma. Oncotarget2019;
10:5645–59
106.
SchiapparelliPEnguita-GermanMBalbuenaJReyJALazcozPCastresanaJS.Analysis of stemness gene expression and CD133 abnormal methylation in neuroblastoma cell lines. Oncol Rep2010;
24:1355–62
107.
KhalilMAHrabetaJGrohTProchazkaPDoktorovaHEckschlagerT.Valproic acid increases CD133 positive cells that show low sensitivity to cytostatics in neuroblastoma. PLoS One2016;
11:e0162916
108.
TakenobuHShimozatoONakamuraTOchiaiHYamaguchiYOhiraMNakagawaraAKamijoT.CD133 suppresses neuroblastoma cell differentiation via signal pathway modification. Oncogene2011;
30:97–105
109.
KhalilMAHrabetaJCiproSStiborovaMVichaAEckschlagerT.Neuroblastoma stem cells – mechanisms of chemoresistance and histone deacetylase inhibitors. Neoplasma2012;
59:737–46
110.
ZhongZYShiBJZhouHWangWB.CD133 expression and MYCN amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma. J Int Med Res2018;
46:1209–20
111.
BajGTongiorgiE.BDNF splice variants from the second promoter cluster support cell survival of differentiated neuroblastoma upon cytotoxic stress. J Cell Sci2009;
122:36–43
112.
SarteletHImbriglioTNyalendoCHaddadEAnnabiBDuvalMFetniRVictorKAlexendrovLSinnettDFabreMVassalG.CD133 expression is associated with poor outcome in neuroblastoma via chemoresistance mediated by the AKT pathway. Histopathology2012;
60:1144–55
113.
PittoniPPiconeseSTripodoCColomboMP.Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors. Oncogene2011;
30:757–69
114.
HuttKJMcLaughlinEAHollandMK.Kit ligand and c-Kit have diverse roles during mammalian oogenesis and folliculogenesis. Mol Hum Reprod2006;
12:61–9
115.
LauSTHansfordLMChanWKChanGCWanTSWongKKKaplanDRTamPKNganES.Prokineticin signaling is required for the maintenance of a de novo population of c-KIT+ cells to sustain neuroblastoma progression. Oncogene2015;
34:1019–34
116.
JogiAOraINilssonHLindeheimAMakinoYPoellingerLAxelsonHPahlmanS.Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc Natl Acad Sci USA2002;
99:7021–6
117.
Saint-AndreVFederationAJLinCYAbrahamBJReddyJLeeTIBradnerJEYoungRA.Models of human core transcriptional regulatory circuitries. Genome Res2016;
26:385–96
118.
BoevaVLouis-BrennetotCPeltierADurandSPierre-EugèneCRaynalVEtcheversHCThomasSLermineADaudigeos-DubusEGeoergerBOrthMFGrünewaldTGPDiazEDucosBSurdezDCarcabosoAMMedvedevaIDellerTCombaretVLapoubleEPierronGGrossetête-LalamiSBaulandeSSchleiermacherGBarillotERohrerHDelattreOJanoueix-LeroseyI.Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries. Nat Genet2017;
49:1408–13
119.
van GroningenTKosterJValentijnLJZwijnenburgDAAkogulNHasseltNEBroekmansMHaneveldFNowakowskaNEBrasJvan NoeselCJMJongejanAvan KampenAHKosterLBaasFvan Dijk-KerkhovenLHuizer-SmitMLeccaMCChanALakemanAMolenaarPVolckmannRWesterhoutEMHamdiMvan SluisPGEbusMEMolenaarJJTytgatGAWestermanBAvan NesJVersteegR.Neuroblastoma is composed of two super-enhancer-associated differentiation states. Nat Genet2017;
49:1261–6
120.
LynchJFayJMeehanMBryanKWattersKMMurphyDMStallingsRL.MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-beta signalling pathway. Carcinogenesis2012;
33:976–85
121.
ChenYStallingsRL.Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res2007;
67:976–83
122.
StallingsRL.MicroRNA involvement in the pathogenesis of neuroblastoma: potential for microRNA mediated therapeutics. Curr Pharm Des2009;
15:456–62
123.
BrodeurGM.Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer2003;
3:203–16
124.
BiedlerJLRoffler-TarlovSSchachnerMFreedmanLS.Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res1978;
38:3751–7
125.
BreitSAshmanKWiltingJRosslerJHatziEFotsisTSchweigererL.The N-myc oncogene in human neuroblastoma cells: down-regulation of an angiogenesis inhibitor identified as activin A. Cancer Res2000;
60:4596–601
126.
YusufMLeungKMorrisKJVolpiEV.Comprehensive cytogenomic profile of the in vitro neuronal model SH-SY5Y. Neurogenetics2013;
14:63–70
127.
Niewiarowska-SendoAPatrzalekKKozikAGuevara-LoraI.The effect of differentiation agents on inflammatory and oxidative responses of the human neuroblastoma cell line SK-N-SH. Acta Biochim Pol2015;
62:435–43
128.
KeshelavaNTsao-WeiDReynoldsCP.Pyrazoloacridine is active in multidrug-resistant neuroblastoma cell lines with nonfunctional p53. Clin Cancer Res2003;
9:3492–502
129.
KryhHCarenHErichsenJSjobergRMAbrahamssonJKognerPMartinssonT.Comprehensive SNP array study of frequently used neuroblastoma cell lines; copy neutral loss of heterozygosity is common in the cell lines but uncommon in primary tumors. BMC Genomics2011;
12:443
130.
ThieleCJ.Neuroblastoma cell lines. Human Cell Culture1998;
1:32
131.
KeshelavaNSeegerRCGroshenSReynoldsCP.Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res1998;
58:5396–405
132.
GilbertFFederMBalabanGBrangmanDLurieDKPodolskyRRinaldtVVinikoorNWeisbandJ.Human neuroblastomas and abnormalities of chromosomes 1 and 17. Cancer Res1984;
44:5444–9
133.
MahllerYYWilliamsJPBairdWHMittonBGrossheimJSaekiYCancelasJARatnerNCripeTP.Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS One2009;
4:e4235
134.
SchleiermacherGJanoueix-LeroseyICombaretVDerréJCouturierJAuriasADelattreO.Combined 24-color karyotyping and comparative genomic hybridization analysis indicates predominant rearrangements of early replicating chromosome regions in neuroblastoma. Cancer Genet Cytogenet2003;
141:32–42
135.
CarrJBellEPearsonADKeesURBerisHLunecJTweddleDA.Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse. Cancer Res2006;
66:2138–45
136.
KanekoTOkitaHNakajimaHIijimaKOgasawaraNMiyagawaYKatagiriYUNakagawaAKiyokawaNSatoTFujimotoJ.Neuroblastoma cells can be classified according to glycosphingolipid expression profiles identified by liquid chromatography-tandem mass spectrometry. Int J Oncol2010;
37:1279–88
137.
CrawfordSEStellmachVRanalliMHuangXHuangLVolpertODe VriesGHAbramsonLPBouckN.Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity. J Cell Sci2001;
114:4421–8
138.
BrodeurGMSekhonGGoldsteinMN.Chromosomal aberrations in human neuroblastomas. Cancer1977;
40:2256–63
139.
VoigtAHartmannPZintlF.Differentiation, proliferation and adhesion of human neuroblastoma cells after treatment with retinoic acid. Cell Adhes Commun2000;
7:423–40
SanmartínEMuñozLPiquerasMSirerolJABerlangaPCañeteACastelVFont de MoraJ.Deletion of 11q in neuroblastomas drives sensitivity to PARP inhibition. Clin Cancer Res2017;
23:6875–87
142.
GogolinSEhemannVBeckerGBruecknerLMDreidaxDBannertSNolteISavelyevaLBellEWestermannF.CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage. Cell Cycle2013;
12:1091–104
143.
MiddlemasDSStewartCFKirsteinMNPoquetteCFriedmanHSHoughtonPJBrentTP.Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res2000;
6:998–1007
144.
DakicADiVitoKFangSSuprynowiczFGaurALiXPalechor-CeronNSimicVChoudhurySYuSSimbulan-RosenthalCMRosenthalDSchlegelRLiuX.ROCK inhibitor reduces myc-induced apoptosis and mediates immortalization of human keratinocytes. Oncotarget2016;
7:66740–53
145.
LiuXOryVChapmanSYuanHAlbaneseCKallakuryBTimofeevaOANealonCDakicASimicVHaddadBRRhimJSDritschiloARiegelAMcBrideASchlegelR.ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am J Pathol2012;
180:599–607
146.
LiuXKrawczykESuprynowiczFAPalechor-CeronNYuanHDakicASimicVZhengYLSripadhanPChenCLuJHouTWChoudhurySKallakuryBTangDGDarlingTThangapazhamRTimofeevaODritschiloARandellSHAlbaneseCAgarwalSSchlegelR.Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens. Nat Protoc2017;
12:439–51
147.
TimofeevaOAPalechor-CeronNLiGYuanHKrawczykEZhongXLiuGUpadhyayGDakicAYuSFangSChoudhurySZhangXJuALeeMSDanHCJiYHouYZhengYLAlbaneseCRhimJSchlegelRDritschiloALiuX.Conditionally reprogrammed normal and primary tumor prostate epithelial cells: a novel patient-derived cell model for studies of human prostate cancer. Oncotarget2017;
8:22741–58
148.
MahajanASSugitaBMDuttargiANSaenzFKrawczykEMcCutcheonJNFonsecaASKallakuryBPohlmannPGusevYCavalliLR.Genomic comparison of early-passage conditionally reprogrammed breast cancer cells to their corresponding primary tumors. PLoS One2017;
12:e0186190
149.
KrawczykEHongSHGalliSTrinhEWietlisbachLMisiukiewiczSFTilanJUChenYSSchlegelRKitlinskaJ.Murine neuroblastoma cell lines developed by conditional reprogramming preserve heterogeneous phenotypes observed in vivo. Lab Invest2020;
100:38–51
150.
NakagawaMKoyanagiMTanabeKTakahashiKIchisakaTAoiTOkitaKMochidukiYTakizawaNYamanakaS.Generation of induced pluripotent stem cells without myc from mouse and human fibroblasts. Nat Biotechnol2008;
26:101–6
151.
TakahashiKYamanakaS.Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell2006;
126:663–76
152.
ChaoHMChernE.Patient-derived induced pluripotent stem cells for models of cancer and cancer stem cell research. J Formos Med Assoc2018;
117:1046–57
153.
PapapetrouEP.Patient-derived induced pluripotent stem cells in cancer research and precision oncology. Nat Med2016;
22:1392–401
154.
YoshidaGJ.Applications of patient-derived tumor xenograft models and tumor organoids. J Hematol Oncol2020;
13:4
155.
FanHDemirciUChenP.Emerging organoid models: leaping forward in cancer research. J Hematol Oncol2019;
12:142
156.
YangHSunLLiuMMaoY.Patient-derived organoids: a promising model for personalized cancer treatment. Gastroenterol Rep (Oxf)2018;
6:243–5
157.
NaglePWPlukkerJTMMuijsCTvan LuijkPCoppesRP.Patient-derived tumor organoids for prediction of cancer treatment response. Semin Cancer Biol2018;
53:258–64
158.
LannaganTRMLeeYKWangTRoperJBettingtonMLFennellLVrbanacLJonaviciusLSomashekarRGieniecKYangMNgJQSuzukiNIchinoseMWrightJAKobayashiHPutoczkiTLHayakawaYLeedhamSJAbudHEYilmazOHMarkerJKlebeSWirapatiPMukherjeeSTejparSLeggettBAWhitehallVLJWorthleyDLWoodsSL.Genetic editing of colonic organoids provides a molecularly distinct and orthotopic preclinical model of serrated carcinogenesis. Gut2019;
68:684–92
159.
StewartEFedericoSMChenXShelatAABradleyCGordonBKarlstromATwarogNRClayMRBahramiAFreemanBB3rdXuBZhouXWuJHonnellVOcarzMBlankenshipKDapperJMardisERWilsonRKDowningJZhangJEastonJPappoADyerMA.Orthotopic patient-derived xenografts of paediatric solid tumours. Nature2017;
549:96–100
160.
FuscoPParisattoBRampazzoEPersanoLFrassonCDi MeglioALeslzASantoroLCafferataBZinACimettaEBassoGEspositoMRToniniGP.Patient-derived organoids (PDOs) as a novel in vitro model for neuroblastoma tumours. BMC Cancer2019;
19:970
